Posted by Michael Wonder on 30 Jan 2022
European Commission approves Lorviqua (lorlatinib) as a first-line treatment for ALK positive advanced lung cancer
28 January 2022 - Approval based on results from Phase 3 CROWN trial, showing Lorviqua reduced risk of disease progression or death by 72% in newly diagnosed individuals compared to Xalkori (crizotinib).
Pfizer announced today that the European Commission granted marketing authorisation for Lorviqua (lorlatinib, available in the U.S. under the brand name Lorbrenna as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously not treated with an ALK inhibitor.
